Development of Good Cancer Drugs Effective against Cancer Stem Cells
Published: 2023-12-07
Page: 238-247
Issue: 2023 - Volume 6 [Issue 2]
Ming C. Liau *
CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.
Christine L. Craig
CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.
Linda L. Baker
CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.
*Author to whom correspondence should be addressed.
Abstract
A right approach is essential to solve any illness. Cancer mortality remains at historic high and is still on the way to increase. The objective of this study is to find a right approach of cancer therapy to bring cancer mortality down. Myelodysplastic syndromes are diseases attributable entirely to cancer stem cells that can be used to screen good cancer drugs to bring down cancer mortality. Cancer is caused due to wound unhealing. Wound triggers biological and immunological responses. Biological response leads to the production of prostaglandins (PGs) which are good for wound healing. Immunological response prompts the production of tumor necrosis factor (TNF) which is bad for wound healing. TNF causes apoptosis of stem cells, thus triggering the proliferation of progenitor stem cells (PSCs) to repair wound damages. TNF is also named cachectin after its effect to cause cachexia symptom. A manifestation of cachexia symptom is the excessive urinary excretion of low molecular weight metabolites, resulting in the collapse of chemo-surveillance which is the nature’s creation of allosteric regulation to keep a check on abnormal methylation enzymes (MEs). PSCs are cells with abnormal MEs. On wound healing, efficient terminal differentiation of PSCs is a critical mechanism to heal wound. If wound is not healed properly, PSCs may be forced to evolve into cancer stem cells (CSCs) through a single hit to silence TET-1 enzyme, and then to progress to faster growing cancer cells (CCs) through chromosomal abnormalities such as translocations or deletions to activate oncogenes or to inactivate suppressor genes. Myelodysplastic syndromes (MDS) are a classic case of cancer development at the stage of PSCs evolving to become CSCs. Therapy of MDS requires the differentiation of pathological CSCs to become functional erythrocytes, platelets or neutrophils. So far, Vidaza, Decitabine and cell differentiation agent-2 (CDA-2) are the three drugs approved for the therapy of MDS. Vidaza and Decitabine inactivate abnormal MEs through covalent bone formation between DNA methyltransferase and 5-azacytosine base incorporated into DNA, whereas CDA-2 destabilizes abnormal MEs through elimination of telomerase. Obviously, inactivation of abnormal MEs is the only way to achieve therapy of MDS. Elimination of CSCs is very critical to the success of cancer therapy. Thus, MDS can be used to screen good cancer drugs to fulfill the wish of President Biden to reduce cancer mortality.
Keywords: Cancer drugs, CDA-2, CSCs, MDS, abnormal MEs, PSCs, wound healing
How to Cite
Downloads
References
Google search on cancer statistics-NCI.
Liau MC, Fruehauf JP. It has been half a century since President Nixon declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. Adv Complement Alt Med. 2020;6(1):538-539.
Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol. 2022;6(3):8-20.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: Nature’s way to eradicate cancer stem cells. Online J Complement Alt Med; 2019. DOI: 10.33552/OJCAM.02.000546.
Liau MC, Baker LL. Cancer patients’ lives matter. Adv. Complement Alt Med. 2021;6(1):638-640.
Liau MC, Craig CL, Baker LL. CDA formulations to fulfill cancer moonshot and to win the war on cancer. Intl J Res Oncol. 2023;2(2):1-8.
Liau MC, Craig CL, Baker LL. Restoration of chemo-surveillance as a top priority to save cancer patients. Intl Res J Oncol. 2023;6(2):227-237.
Liau MC, Fruehauf JP. Cancer moonshot: Moonshot as a magic code to guide successful solutions of tough challenges such as cancer. Intl J Res Oncol. 2023;2(1):1-5.
Williamson PJ, Kruger AR, Reynolds PJ, Hamlin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndromes. Br J Haemato. 1994; 87(4):743-745.
Boula A, Vougarelis M, Giannouli S, Katrinakis G, Psyllaki M, Pontikoglou C, et al. Effect of CA2 of antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006;12(10):3099-3108.
Itkin T, Rafii S. Leukemia cells “gas up” leaky bone marrow blood vessels. Cancer Cell. 2017; 32(3):276-278.
Passaro D, Di Tullio A, Abarrategi A, Rousault-Pierre K, Foster K, Ariza-McNaughton L, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell. 2017;32(3):324-341.
Liau MC, Craig CL, Liau LL. Abnormal methylation enzymes as the most critical issue of cancer. Intl Res J Oncol. 2023;6(2):168-176.
Liau MC, Chang CF, Giovanella BC. Demosstration of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980;64(5):1071-1075.
Liau MC, Baker LL. Abnormal methylation enzymes as the bullseye of targeted cancer therapy. Nov Res Sci. 2021;7(4):1-3.
Liau MC, Craig CL, Baker LL. Exceptional allosteric regulation of methylation enzymes. In: Saraydin SU (ed): Novel Research Aspects in Medicine and Medical Science. 2023;4:39-56. DOI: 10.9734/bpi/nramms/v4/19881D.
Liau MC, Chang CF, Saunder GF, Tsai YH. S-adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981; 208(1): 261-272.
Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Clin Oncol Cancer Res. 2010;7(2):86-96.
Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res. 1989;13(Suppl. 1):72-82.
Racanelli AC, Turner FB, Xie LY, Taylor SM, Meran RG. A mouse gene that coordinate epigenetic controls and transcriptional interference to achieve tissue specific expression. Mol Cell Biol. 2008;28(2):836-848.
Liau MC, Hunt ME, Hurlbert RB. Role of ribosomal RNA methylases in the regulation of ribosome production. Biochemistry. 1976;15(14):3158-3164.
Bernstein KA, Bleichert F, Bean JM, Cross FR, Baserga SJ. Ribosome biogenesis is sensed at the start cell cycle check point. Mol Biol Cell. 2007;18(3):953-964.
Justilien Y, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, et al. ECT2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma. Cancer Cell. 2017;31(2):256-269.
Liau MC, Lin GW, Hulbert RB. Partial purification and characterization of tumor and liver S-adenosylmethionine synthetases. Cancer Res. 1977;37(2):427-435.
Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stu Ther. 2019;4(1):1-15.
Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers to combat cancer via targeting of abnormal methylation enzymes. J Cancer Tumor Intl. 2020;10(2):39-47.
Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. Clin Pharmacol Toxicol Res. 2021;4(1):7-10.
Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin cancer. 2002;11:166-168.
Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HL-60 cells by targeting methylation enzymes. J Pharmacol Pharmaceut Pharmacovig. 2019;3:009. DOI: 10.24966/PPP-5649/100009.
Morley JE. Hormone, aging, and endocrines in the elderly. In: Felig P, Frohman LA, “Endocrinology and Metabolism, 4th edn, 2001, McGrow-Hill, Inc., Medical Publishing Division, New York, pages 1455-1482.
Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. Cancer Res. 1979;39(6):2113-2119.
Kamparath BN, Liau MC, Burzynski B, Burzynski SR. Protective effect of Antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Intl J Tiss React. 1990;12(Suppl.):43-50.
Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells. Therefore, non-destruction is a better strategy for cancer therapy: A commentary. J Pharmacol Pharmaceut Pharmacovig. 2020;4:029. DOI:10.24966/PPP-5649/100029.
Virchow R. Die Cellular Pathologie in Ihrer Begrundung auf Physiologische und Pathologische Gewebelehve. Hirschwald. 1858;16:440.
Dvorak HF. Tumors: Wounds that do not heal. N Engl J Med. 1986;315(26):1650-1659.
MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020;13:648.
Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021;7(2):1-3.
Liau MB Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: New Horrizons in Medicine and Medical Research. 2022; Vol. 6, Chapter 3. Print ISBN: 978-93-5547-607-4.
Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Intl J Exptl Clin Chemother. 1989;2:187-199.
Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol. 2021;5(3):25-31.
Liau Craig CL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. J Cancer Tumor Intl. 2022;12(1):29-34.
Liau MC, Craig CL, Baker LL. Wound unhealing as a grave issue of cancer. Intl Res J Oncol. 2023;6(1):97-103.
Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 2012; 103(4):670-678.
Ficz GM, Gibben JG. Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? Genomics. 2014;104(5): 352-357.
Liau MC, Craig CL, Baker LL. Wound healing process as the most appropriate modality of cancer therapy. Eur J Applied Sci. 2023;11(1):463-471.
Liau MC, Craig CL, Baker LL. A drastic change of cancer leaderships to save desperate cancer patients. In: Gurunathan R (ed), New Advances in Medicine and Medical Science, 2023;7(6):61-69. DOI: 10.9734/bpi/namms/v7/19537D.
Ho ATV, Palla AR, Blake MR, Yual ND, Wang ND, Magnusson KEG, et al. Prostaglandin E2 is essential for efficacious skeletal muscle stem function, augmenting regeneration and strength. Proc Natl Acad Sci USA. 2017;114(26):6675-6634.
Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent. 2007;7232578 B2.
Ma J. Differentiation therapy of malignant tumor and leukemia. CSCO Treaties on the Education of Clinical Oncology. 2007;480-486.
Prassana P, Shack S, Wilson VL. Samid D. Phenylacetate in chemoprevention of 5-aza-2’-deoxycytidine-induced carcinogensis. Clin Cancer Res. 1995;1(18):865-871.
Gaudet F, Hodgson JG, Eden A. Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumor in mice by genomic hypomethylation. Science. 2003;300 (5618):489-492.
Palii SS, van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DAN methylation inhibitor 5-aza-2‘-deoxycytidine-induces reversible DAN damage that is distinctly influenced by DAN-methyltransferase 1 and 3B. Mol Cell Biol. 2008;28(2):752-771.
Kizietepe T, Hideshima T, Catley L, Raje N, Yasui H, Shirishi N, et al. 5-Azacytidine, a methyltransferase inhibitor, induces ATR-mediated DNA-double strand break responses, apoptosis and synergistic cytotoxicity with doxorubicine and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718-1727.
Yang Q, Wu F, Wang F, Cai K, Zhang Y, Sun Q, et al. Impact of DNA methyltransferase inhibitor 5-azacytidine on cardiac development of zebrafish in vivo and cardiomyocyte proliferation, apoptosis, and homeostasis of gene expression In vitro. J Cell Biochem. 2019; 120(10):17459- 17471.
Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA. 1984;81(22): 6993-6997.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing. 2020; 978-620-2-66889-7.